Despite increased data sets of potential drug targets and their structural characterization, drug discovery has been waning for over a decade (Loscalzo 2012). In part, this limitation is a consequence of the reductionist approach to discovery, which seeks a single molecular cause for each disease that can be targeted with an Ehrlichian magic bullet.
